Featured Studies Results

Study Type: Treatment | Keyword: BRCA2

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer identifier:
NCT04674306 (

Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study) identifier:
NCT05417594 (

Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib identifier:
NCT04550494 (

Treatment study for people with advanced solid tumors

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI) identifier:
NCT03462342 (

Recurrent ovarian cancer

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO) identifier:
NCT04858334 (


Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA) identifier:
NCT04038502 (

Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells identifier:
NCT04150042 (

Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation identifier:
NCT04584255 (

Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA) identifier:
NCT04644068 (

Advanced ovarian, breast, prostate or pancreatic cancer

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation identifier:
NCT04548752 (

Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy identifier:
NCT04666740 (


A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded) identifier:
NCT03344965 (


Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations identifier:
NCT03990896 (



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.